Form 8K ADAPTI For: 6 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptimmune Therapeutics Plc ADR (ADAPY)
Adaptimmune Therapeutics Plc ADR stock price live, this page displays OTC ADAPY stock exchange data. View the ADAPY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptimmune Therapeutics Plc ADR real time stock price chart below.
What Is the Adaptimmune Therapeutics Plc ADR Stock Price Today?
The Adaptimmune Therapeutics Plc ADR stock price today is 0.026.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc ADR?
The stock symbol for Adaptimmune Therapeutics Plc ADR is "ADAPY."
What Stock Exchange Does Adaptimmune Therapeutics Plc ADR Trade On?
Adaptimmune Therapeutics Plc ADR is listed and trades on the OTC Markets stock exchange.
Is Adaptimmune Therapeutics Plc ADR a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAPY quote. (ISIN: US00653A1079)
What Is the Adaptimmune Therapeutics Plc ADR Stock Price Today?
The Adaptimmune Therapeutics Plc ADR stock price today is 0.026.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc ADR?
The stock symbol for Adaptimmune Therapeutics Plc ADR is "ADAPY."
What Stock Exchange Does Adaptimmune Therapeutics Plc ADR Trade On?
Adaptimmune Therapeutics Plc ADR is listed and trades on the OTC Markets stock exchange.
Is Adaptimmune Therapeutics Plc ADR a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAPY quote. (ISIN: US00653A1079)
0.026
-0.001(-2.99%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.018
0.027
52 wk Range
0.001
0.275
ADAPY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0180.027
52 wk Range
0.0010.275
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADAPY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Adaptimmune Therapeutics Plc ADR SWOT Analysis
TCR-T Breakthrough | Adaptimmune's early FDA approval of Tecelra for synovial sarcoma marks a significant milestone in T-cell receptor engineered therapies |
Financial Crossroads | Despite impressive revenue growth, Adaptimmune faces challenges with negative EPS forecasts and a revised cash runway extending into late 2025 |
Market Dynamics | Explore Adaptimmune's pioneering position in the TCR-T market, balanced against the $727,000 list price for Tecelra and potential adoption hurdles |
Future Prospects | Analyst price targets hover around $1.00, reflecting cautious optimism as Adaptimmune navigates commercialization challenges and pipeline development |
Adaptimmune Therapeutics Plc ADR Earnings Call Summary for Q1/2025
- Q2 2025 revenue beat at $13.67M, 22.16% above forecast; EPS of -$0.02 better than expected -$0.05
- Stock dipped 5.08% pre-market to $0.0729, despite revenue beat, reflecting investor concerns
- Full-year revenue guidance of $35M-$45M from TESULRA sales; preparing for Leticel launch in 2026
- 100% manufacturing success rate highlighted; cash runway less than 12 months poses sustainability risk
- Financial health score 'WEAK' at 1.11; negative free cash flow yield of -12.69% and Altman Z-Score of -33.7
Last Updated: 08/21/2025, 07:52 PM
Read Full TranscriptEarnings
Latest Release
Aug 31, 2026
EPS / Forecast
-- / -0.02
Revenue / Forecast
-- / --
Compare ADAPY to Peers and Sector
Metrics to compare | ADAPY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAPYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −2.6x | −0.4x | |
PEG Ratio | 0.00 | −0.02 | 0.00 | |
Price/Book | 0.2x | 2.6x | 2.6x | |
Price / LTM Sales | 1.2x | 6.9x | 3.0x | |
Upside (Analyst Target) | - | 369.1% | 57.5% | |
Fair Value Upside | Unlock | 7.2% | 7.8% | Unlock |
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Adaptimmune Therapeutics ADR (ADAPY) Stock Price Today?
The Adaptimmune Therapeutics ADR stock price today is 0.026 USD.
What Stock Exchange Does Adaptimmune Therapeutics ADR Trade On?
Adaptimmune Therapeutics ADR is listed and trades on the OTC Markets.
What Is the Stock Symbol for Adaptimmune Therapeutics ADR?
The stock symbol for Adaptimmune Therapeutics ADR is "ADAPY."
What Is the Adaptimmune Therapeutics ADR Market Cap?
As of today, Adaptimmune Therapeutics ADR market cap is 7.100M USD.
What Is Adaptimmune Therapeutics ADR's Earnings Per Share (TTM)?
The Adaptimmune Therapeutics ADR EPS (TTM) is -0.300.
When Is the Next Adaptimmune Therapeutics ADR Earnings Date?
Adaptimmune Therapeutics ADR will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is ADAPY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Adaptimmune Therapeutics ADR Stock Split?
Adaptimmune Therapeutics ADR has split 0 times.
How Many Employees Does Adaptimmune Therapeutics ADR Have?
Adaptimmune Therapeutics ADR has 272 employees.
What is the current trading status of Adaptimmune Therapeutics ADR (ADAPY)?
As of Sep 29, 2026, Adaptimmune Therapeutics ADR (ADAPY) is trading at a price of 0.026 USD, with a previous close of 0.027 USD. The stock has fluctuated within a day range of 0.018 USD to 0.027 USD, while its 52-week range spans from 0.001 USD to 0.275 USD.
What Is the ADAPY After Hours Price?
ADAPY's last after hours stock price is 0.010 USD, the stock has decreased by 0.006, or 156.410%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.